Company: MYSZ
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001493152-25-009696
Chunk: 1

Company: My Size, Inc.
Filing Date: 2025-03-10
Form: 8-K
Item: Item 5.02
Chunk 1
---
2018 to 2019, Mr. Golan served as President and Chief Financial Officer of Exalenz Bioscience
Ltd. (TASE: EXEN), a Tel Aviv Stock Exchange listed global, commercial-stage diagnostics company which developed its BreathID® technology
platform to improve patient care by providing breath-based tests in the fields of gastroenterology and hepatology and was later acquired
by Meridian Bioscience, Inc. (NASDAQ: VIVO). From 2015 to 2018, Mr. Golan served as the Chief Financial Officer of NeuroDerm (NASDAQ:
NDRM), a Nasdaq listed clinical-stage pharmaceutical company developing next-generation drug-device combinations for central nervous
system disorders, through its initial public offering until its acquisition by Mitsubishi Tanabe Pharma Group Company, and prior thereto
he served as their VP Finance. Mr. Golan holds an LLM from Bar Ilan University as well as a BA from The College of Management in Rishon
LeZion and is also a licensed CPA.